A phase IIa trial investigating the tolerability and pharmacodynamics of Vacc 4x (0.1 or 0.3 mg/dose) for the treatment of HIV-1 infections.

Trial Profile

A phase IIa trial investigating the tolerability and pharmacodynamics of Vacc 4x (0.1 or 0.3 mg/dose) for the treatment of HIV-1 infections.

Completed
Phase of Trial: Phase II

Latest Information Update: 17 Oct 2013

At a glance

  • Drugs Vacc-4x (Primary) ; Molgramostim
  • Indications HIV-1 infections
  • Focus Adverse reactions; Pharmacodynamics
  • Most Recent Events

    • 17 Oct 2013 The reboost study will be presented at the Global Health and Vaccination Research conference.
    • 07 Aug 2013 Results from the first re-boost clinical trial of Vacc-4x, up to 7 years after the initial vaccination, have been accepted for publication in Vaccine, according to a Bionor Pharma media release.
    • 22 Jul 2010 Results in 22 patients 7 years postvaccination (prior to the reboost) reported as a Late-Breaker abstract at the XVIII International AIDS Conference, according to a Bionor Immuno media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top